GENERIC COMPETITION NEW PRODUCT
THE INDIAN GROUP
The leaders of this group are Ranbaxy
Laboratories Ltd, Reddy's Laboratories and
Wockhardt. They are ready to make inroad in
Dr. Reddy's Laboratories Ltd
(1)Dr. Reddy's (RDY) had filed an ANDA with
FDA for Moxifloxacin tablets 400 mg, with a
Paragraph IV certification. Moxifloxacin is the
generic version of Bayer's Avelox with
market of 207 million in the US.
(2)They also have the first-to file status
along with one other filer for Levetiracetam
Tablets, on all dosage strengths and if
successful in its litigation, would enjoy a
180-day marketing co-exclusivity.
Levetiracetam is the generic version of
UCB's Keppra(TM) and its market are appr.
$234 million in the US.
(3) It gave notice it is looking to produce
cheap generic version of
Seroquel.&nbsp; AstraZeneca Plc said
it had &quot;every
confidence&quot; in the patent
protecting its Seroquel, despite moves by Dr
Reddy's that could presage a generic
challenge in the US.
(4) Dr Reddy's launched Redotil for
management of acute diarrhoea in April,
Related News:(1)Dr. Reddy's Announccs
ANDA Filing for Moxifloxacin Tablet; March
29, 2004 (2)Dr. Reddy's Announces ANDA
Filing for Levetiracetem Tablet, March
22,2004 (3) AstraZeneca faces generic
threat, by Tudor et al, Reuters UK, April 16,
2004 (4) Drug Reddy's launches drug for
diarrhoea, Business Line, April 3, 2004.
Ranbaxy' ambition April 1, 2004
Ranbaxy has products in 100 countries, its
total sales of pharmaceuticals in India was
$5 billion last year. It has 81 generic
products approved by the US FDA and 40
pending approvals. Last year, Ranbaxy
spent $60 million (6% of its revenues) on
R&D;And, it plans to expand its
R&D to 10%. It also have NDA
programs. Its experimental molecule,
SPM969 for treating prostate enlargement,
was licensed to Schwarz Pharma and now
this experimental drug is in phase one trial.
Ranbaxy is also working with Glaxo to
commercialize a few promising
compounds. In addition to the new
compounds, Ranbaxy is&nbsp; also
active to develop novel drug delivery
systems, such as once-a-day version for
ciprofloxacin. It has 15 or more of improved
generics in the pipeline.
Ranbaxy gets tentative U.S. nod for
generic Accupril March 15, 2004
Ranbaxy's drug was a generic form of Pfizer
Inc's antihypertension drug Accupril which
had sales worth $589 million in 2003 in the
Indian pharma giants make
inroads in the US...March 14, 2004
India's pharmaceuticals giants like Ranbaxy
Laboratories Ltd, Reddy's Laboratories,
Wockhardt among others are making
sure-footed moves to secure a bigger global
THE US COMPANIES'Teva Pharmaceuticals.
Forest Lab. receives notification of ANDA
filing for a generic equivalent with a
Paragraph IV Certification of
Alphapharm Pty. Ltd. an Australian unit of
Merck KGaA has filed with the US FDA
seeking a generic version too.
Related News: Forest Labs says competitor
seeking Lexapro copy, Reuters, April 16,
MYLAN's NEW MOVES
FDA granted Mylan to market generic
versions of the popular thyroid drug
levothyroxine sodium. Sales of Levoxyl in
2003 were $134 million.
Source Levoxyl rivals' approval undercuts
King, by Val Brickates Kennedy, CBS
MarketWatch.com, June 24, 2004.
Aprokyn FDA approved Apokyn, an injectable
drug to treat periods of immobility in patients
with Parkinson's disease. About 1.5 million
Americans have Parkinson's. Related
News: US FDA OKs Bertek drug for
Parkinson's immobility, Reuters, April 21,
Nitrofurantoin Mylan Receives FDA Approval
and 180 Day Exclusivity for Nitrofurantoin
(copycat for PG's Macrobid). Related News:
Mylan Receives FDA Approval and 180 Day
Exclusivity for Nitrofurantoin March 24,
2004.RisperidoneRisperidone is the copycat of
Janssen Pharmaceutical's Risperdal Tablet.
Mylan may have one of ten potential first-to-file
opportunities. Related News: Mylan Announces
Tentative Approval for Risperidone
Tablets.Fentanyl A federal court in Vermont
ruled Mylan's copycat version of a pain patch
violated J&amp;J patent.The US sales for
that product (fentanyl) were $1.27 billion in
2003. And, the FDA approved Mylan's generic
version of the patch last year. Related News:A
federal court in Vermont ruled Mylan's copycat
version of a pain patch violated J&amp;J
patent. March 26, 2004
There are more than 10 million Americans
suffering from chronic pain with a minized
ptential for abuse. These are the first
generic versions of the potent painkiller
Oxycontin approved for market.
Related News: FDA cleared Endo and Teva
Pharmaceuticals to sell copycat version of
extended-release oxycodone (Oxycontin)
March 24, 2004
King Pharmaceuticals Responds to Letter to
ANDA Applicants for Skelaxin (R). March 12,
The letter stated that ANDA applicants may
delete the use listed in the Orange Book for
U.S. Patent No. 6,407,128 from their product
(1) Ivax launches glyburide/metformin HCl
Tablets and Triggers 180 day marketing
exclusivity. The market for the
branded-product, Glucovance, was about
$500 million in 2003.
Extracted from:Ivax' news release on May 4,
(2) IVAX recieves tentative approval for fluconazole
Tablets. The US sales for this medicine were $475
mllion druing 2003. Related News: IVAX recieves
tentative approval for fluconazole
Tablets&nbsp;&nbsp;&nbsp; March 18,
(3) European Commission has approved
IVX to market its injectable paclitaxel drug as
a treatment for metastatic breast cancer and
metastatic ovarian cancer. Related News:
Ivax: EU OKs copycat cancer drug, March 11,
(4) Ivax is the first company to challenge the
Zyprexa patent, Ivax would gain 180 days of
market exclusivity for generics at most
doses. Both expect a ruling sometime this
summer. Related News: Eli Lilly's Zyprexa
fortunes rest with courts by Bill Berkrot,
Reuters, April 19, 2004.
Update-Metformin HCl ER Tablet
FDA has granted IMPAX a second tier 180
day exclusivity related to its pending ANDA
for Glucophage XL (Metformin HCl ER
Tablets, 500 mg). BUT, Impax has seletively
waived its rights to this exclusivity to Teva
and will be sharing in the profits of Teva's
Metformin HCl ER Tablets under an
agreement signed in June of 2001. Sales
for this product are $430 million in 12
months ended March 31, 2004.
Source Press Release June 18, 2004.
Lawsuit drops Impax shares March 11, 2004
Aventis, along with partner AMR Technology
Inc., filed patent infringement lawsuits in
U.S. District Court against five companies,
including Impax, that are currently seeking
approval to produce and market generic
versions of Allegra.
FDA OKs Impax' high-dosage form of
Wellbutrin&nbsp; March 22, 3004
The US market in 2003 for Glaxo's 150 mg
Wellbutrin were about $1.3 billion. To
&quot;extend&quot; the profit in
Wellbutrin-market, Glaxo has launched a
controlled-release dosage form of
Wellbutrin-Wellbutrin XL. This product is rapidly
becoming popular, because it only needs to be
Barr Lab. has received tentative approval for
its generic version of Aventis' Allegra-D
extended-release tablets. The company will
launch the product following the resolution
of the patent challenge litigation
surrounding this product. Barr believes it
was the first applicant to file an ANDA with
Paragraph IV patent challenge on some of
the patents relating to the Allegra-D product.
SOURCE Barr gets tentative approval for
Allegra-D extended release tab., Woodcliff
Lake, Pharmabiz.com, July 6, 2004.
Barr Lab. has received approval from FDA
for its application to manufacture and
market a copycat of Galen's Ovcon-35
21-day and 28-day Tablets oral
contraceptive. The annual sales for
Ovcon-35 was $63.1 million. Extracted
fromBarr's Press Release on April 23, 2004.
Clarithromycin ER Tablets
FDA has approved its generic version of
Biaxin XL (Sales in 2003 were $280 million).
Co does not plan to launch the generic
version prior to the patent expiration of May
2005. Source Press Release, June 25,
THE CANADIAN GROUP
Federal Court Rules Copycat Infringes on
Abbott Lab. Patent March 18, 2004
The US District Court in Chicago found that
a product manufactured by Apotex Inc.'s
TorPharm unit infringes on Abbott's patents
for Depakote ($1 billion in sales).
NEW PRODUCT DEVELOPMENT
Impax was granted tentative approval of Allegra-D
from FDA in February 2004. However, Bar
Laboratories brought suit against FDA in an
attempt to prevent the agency from granting the
final approval to IMPAX for the generic version.
Now, Impax has filed a motion in the US District
Court for the District of Columbia to intervene as a
Impax files motion to intervene as defendant in litigation
related to generic Allegra-D, Press Release, Business Wire,
Feb 28, 3005.
FDA approved the use of schering-Plough's
Asmanex(R) Twisthaler(R) 220mcg (mometasone
furoate inhalation powder) for the first-line
maintenance treatment of asthma as preventive
therapy in patients 12 years of age and older.
Currently, about 20 million people suffer from
FDA approves Asmanex(R) (mometasone furoate) for once
daily management of asthma. PR Newswire, March 31,
AVIAN FLU VACCINE
Sanofi pasteur, Swiftwater, PA manufactured an
inactivated vaccine for clinicial trials of total 450
healthy adults for H5N1 avian influenza infection
NIDAID Initiates Trial of Experimental Avian Flu
Vaccinei-Newswire.com, March 25, 2005
HEAD AND NECK CANCER
About 40,000 Americans are diagnosed each year
with oral, head and neck cancers. Radiation is a
standard treatment. Tumors were less likely to
spread in patients who took ImClone Systems'
Erbitux in combination with radiation. Erbitux works
by blocking a protein called epidermal growth
factor which helps tumor cells reproduce.
Extracted fromErbitux Prolongs Survival in Head
and Neck Cancer, Ransdell Pierson, Reuters,
June 5, 2004.
Viventia initates a second Phase I clinical trial for
treatment of head and neck cancer with Proxinium.
Source: Press Release, June 7, 2004
ADVENTRX (ANX) iniiated patient recruitment in
Europe as an extension of its CoFactor first line
Phase II clinical trial in metastatic colorectal
cancer. CoFactor (5,10-methylenetetrahydrofolate),
a form of folic acid, enhances the anti-tumor
effects of 5-fluorouracil (5-FU) while reduces its
SOURCE Press Release July 7 2004.
AnorMED announces new HIV entry inhibitor drug
candidate (AMD070) to advance to Phase II clinical
program. AMD070 targets the CXCR4 chemokine
receptor and prevents HIV from entering and
infecting healthy cells.
SOURCE Press Release July 9, 2004.
230,900 new cases of prostate cancer may occur
this year in the United States. It was found that
men with aggressive prostate cancer treated with
Aventis' Taxotere lived longer than patients treated
with other standard chemotherapy drugs in Phase
III trials. Related NewsAventis Drug Prevails in
Prostate Cancer Trials, by Pierson et al, Reuters,
Jun 7, 2004.
Merck & Co is developing a vaccine called
Gardasil which can protect women against four
strains of the human papillomavirus (HPV). The
papillomavirus are prime cause of cervical cancer
and genital warts. The new vaccine may reach the
market in 2006 to compete with GlaxoSmithKline's
Cervarix. Merk is partnering with Sanofi-Aventis to
seek first regulatory approvals for its vaccine in
Europe. Currently, the cervical cancer victimizes
about 470,000 women a year.
A vaccine for cervical cancer found, Earthtimes.org, April
Pfizer and Coley Pharmaceuticals have entered
into an exclusive global license agreement to
develop, manufacture and commercialize Coley's
ProMune TM (CPG 8909), a toll-like receptor
receptor 9 (TR9) agoinst delivered by
subcutaneous injection for treatment and
prevention of cancers.
Coley may earn up to $455 million plus royalties
from Pfizer based on the successful development
and commercialization of the product.
Reference Pfizer in cancer drug pact with Coley, The
Associated Press, New York, March 24, 2005
Insmed Inc. entered an exclusive option
agreement with University of California, San
Francisco for the patented use of IGF-receptor
antagonists to treat prostate cancer. In 2004,
about 30,000 people died as a result of prostate
Insmed Announces exclusive option agreement with UCSF
for Series..Press Release, March 17, 2005.
HERCEPTIN A recent study showed that
Herceptin, an antibody-based drug, helps women
fight an aggressive form of early-stage breast
cancer after surgery. The estimated sales for
Herceptin in 2009 is about 4.2 billion francs.
Roche's Breast Cancer Drug Gets More Positive Data,
Reuters, April 28, 2005.
Currently, Genentech is marketing Herceptin in the
United States, Chugai in Japan and Roche
internationally.  U.S. sales of Herceptin
(Trastuzumab) increased 19 percent to $129.6
million from $108.7 million in the first quarter of
2004.  Genentech Announces First Quarter 2005
Results, Press Release, April 11, 2005.
FDA recently approved an effective medicine -
Avastin - for colorectal cancers.
The interim results of a late-stage trial showed
that Avastin was successful when used with
chemotherapy in untreated breast cancer which
has spread to other parts of the body. About 8-9%
of women will develop breast cancer during their
Roche's Avastin Works in Third Type of Cancer, Reuters,
April 15, 2005
Sulindac was found to be a highly effective
chemoprevention agent because it worked to
induce expression of the p21 gene in a study of
mouse. Sulindac is a NSAID and a COX-2 inhibitor.
NSAID drug protects against intestinal tumors in mice,
despite poor diet and gene losses, innovations report, April
Phosphagenics Limted's Phospha E(vitamin E
product) reduced LDL-C (bad cholesterol)
concentrations up to 40%.
Phosphagenics Ltd: Successful cholesterol reduction
trials, Press Release, March 31, 2005.
This experimental medicine is amazing.
Torcetrapib can double the level of good
cholesterol and may herald a new way of fighting
heart disease. Its effect on increasing HDL can be
intensified in the presence of Lipitor. On the other
hand, Torcetrapib can enhance Lipitor's effect on
LDL-lowering abilities. Pfizer has a plan to market
torcetrapib in combination with Lipitor.
In addition, Pfizer is developing a
controlled-release dosage form for Torcetrapib. It
could be a osmotic tablet, matrix tablet, coated
swellable form or multiparticulate form. And, in
these dosage forms, they used various methods
to improve the dissolution rate (i.e. absorption),
including amorphourous solid dispersion and
Sources: (1) Update-Pfizer drug boosts 'good&quot;
cholesterol-study by Gene Emery, Reuters, April 7, 2004.
(2) US Patent Application No. 20030198674, Curatolo et
Some 40 million Americans are suffered from
Drugs in development (or new) to treat chronic
sleeplessness: Estorra (Sepracor),
Gaboxadol (Merck), Indiplon (Neurocrine
CONGESTIVE HEART FAILURE
Johnson & Johnson's Natrecor caused a 40-50%
greater risk of reduced kidney function when
compared with more conventional therapies for
Popular heart drug tied to kidney ills, report says,
Stephanie Saul, New York Times, March 22, 2005
GlaxoSmithKline's Wellbutrin XL is used to treat
depression. US sales of Wellbutrin XL tablets
were about $1 billion in 2004. Impax, Abriaka and
Anchen have filed ANDAs for generic versions of
Wellbutrin XL to FDA under Paragraph IV of the
IMPAX announces Biovail's lawsuit related to generic
versions of Wellbutrin XL, Press Release, business Wire,
March 09, 2005 Biovail suing U.S. drug company over
generic Wellbutrin XL, CBS News, March 09, 2005.
FDA accepted Biovail (BVF) and Depomod
(DEPO)' NDA for 500 mg and 1000 mg tablets of
Glumetza(TM), once-a-day, extended release
formulations of metformin. The 500 mg dosage
strength was developed using Depomed's Gastric
Retention (GR(TM)) drug delivery technology and
the 1000 mg dosage strength was developed by
Biovail's Smartcoat delivery technolgy.
According to the news release, diabetes affects 17
million Americans and 90% of diabetics suffer
from type II diabetes.
Source Press Release, June 24, 2004.
Pfizer gets FDA Approval for depo-subQ-provera
104, which is the first new treatment option for the
New Medication helps Women's Pain Problem,
Clickondetroit, March 30, 2005.
Researchers have found that oldermen who are
taking Viagra can develop an eye problem that
may lead to permanent vision loss.
Viagra may cause vision loss, Anthony J. Brown, Reuters,
March 30, 2005
The US Department of Health and Human
Services gave a five-year contract ($97 million) to
Sanofi Pasteur (a subsidiary Sanofi-Aventis) to
speed up production of new influenza vaccines.
Sanofi-Aventis gets flu vaccine contract, The Associated
Press, April 1, 2005.
GROWTH HORMONE INSENSITIVITY SYNDROME
FDA accepted for review Insmed's NDA for
SomatoKine (mecasemin rinfabate) for the
treatment of growth hormone insensitivity
syndrome.SomatoKine is an insulin-like growth
factor I (IGF-I) therapy, orphan drug designation
(less than 200,000 patients in the United States).
FDA accepts for review Insmed's NDA for SomatoKine for
the treatment of growth hormone insensitivity syndrome,
Press Release, March 10, 2005.
Heart Attacks and Strokes
Heart attacks and strokes killed bout 1 million
Drugs in development (or new) for related
diseases: 480848 (prevention of heart attack,
GlaxoSmithKline), Acomplia (combat obesity,
Sanofi-Synthelabo), AGI-1067 (combat artery
inflammation, AtheroGenics), DG031 (combat
artery inflammation, DeCode Genetics), ETC-216
(remove chloesterol from arteries, Pfizer), Exanta
(blood thinning, AstraZeneca), Lipitor-torcetrapib
(raise good cholesterol, Pfizer), Pactimibe (keep
cholesterol not to stick to arteries, Sankyo Pharm.),
PPAR alpha agonist (raise good cholesterol, lower
triglycerides, Eli Lilly), Sitaxsentan (treat pulmonary
hypertension, Encysive Pharm.) and SPP100
(reduce high blood pressure, Novartis).
The FDA has approved Bristol-Myers Squibb's
Baraclude (entecavir) to treat chronic hepatitis B in
adults. About 1.25 million Amercians are infected
with the hepatitis B virus.
FDA Approves New Hepatitis B Treatment, Miranda Hitti,
WebMDHealth, March 30, 2005
HIGH BLOOD PRESSURE (HYPERTENSION)
CVRx' Rheos System device (at experimental
stage) has been implanted in a 36-year-old
woman in controlling wayward blood pressure
through electronic stimulation of neck-artery
nerves. Currently, about 65 million American
adults have high blood pressure.
Patient receives blood pressure implant, Ben Dobbin,
Associated Press, April 1, 2005.
HYPERACTIVITY DISORDER ( ATTENTION DEFICIT)
According to Public Cilzen, Abbott's Cylert
(Pemoline) has caused more than 21 cases of
ADHD drug Cylert discontinued, Miranda Hitti, WebMD
Medical News, March 25, 2005
Adderall XR is the lead product in Shire's protfolio.,
Its patents will expire in 2018. Currently, Barr
Laboratories, Impax, Colony and Teva
Pharmaceuticals filed abbreviated new drug
application (ANDA) generic versions of this
Teve files ANDA for generic ADHD drug Adderall, Globes
correspondent, Feb 05, 2005
LIPODYSTROPHY Insmed Inc. initiated a Phase II
clinical trial examining the therapeutic benefit of
treating HIV-associated lipodystrophy with
SomatoKine-once daily IGF-I therapy.
Insmed Initiates Phase II HIV-Associated Lipodystrophy
Trial With Somatokine(R) Insmed Inc. Press Release, April
Mygasthenia gravis is a debilitating neurological
autoimmune disease, in which, autoantibodies
are produce to prevent the nerves from sending
messages to the muscles. Difficulties in
performing simple every-day tasks, breathing and
swallowing may occur. The overall prevalence is
14 per 100,000. Recently, Aspreva's CellCept
enters phase III trial. Source: Company Press, June 7,
MULTIPLE MYELOMA (BLOOD CANCER)
Multiple myeloma affects about 50,000 American.
About 14,600 new cases occur annually.
Celgene's thalidomide was found to be effective
for treating patients with multiple myeloma, a form
of blood cancer in a phase III trial. Related News:
Celgene Says Blood Cancer Patients Respond to Drug,
Reuters, June 7, 2004.
The U.S. FDA approved Millennium Pharmauticals,
Inc.'s supplemental New Drug Applications
(sNDA) for VELCADE on March 25, 2005. The
number of U.S. patients who potentially benefit
from VELCADE is about 22,000.
Millennium to discuss full approval of VELCADE
(bortezomib) for injection in second-line multiple
myeloma, Press Release, March 28, 2005.
Osteoporosis medication - Boniva Boniva for
treating and preventing postmenopausal
osteoporosis was approved by FDA in March
2005. It is being co-promoted by GlaxoSmithKline
and Roche. It is about 44 million Americans older
than 50 suffered from the disease.
Reference FDA OKs Monthly Drug for Osteoporosis,
Associated Press, March 25, 2005
i. Osteoporosis Medicine
NPS Pharmaceuticals Inc. said its experimental
osteoporosis medicine significantly reduced
spinal fractures in a late-stage trial. Preos and
Forteo are similar types of drugs, both are
bioengineered versions of human parathyroid
hormone to keep a constant level of calcium in
body-tissues.Forteo is a hormone fragment while
Preos is the full-length hormone. The projected
annual sales for both Forteo and Preos are about
$400 million. Forteo was launched in November of
2002 and its sales in 2003 were $65 million.
On April 21, 2004, NPS announced that they have
signed a distribution and license agreement with
Nycomed, which granted Nycomed rights to
develop and market PREOS(R) in Europe. In this
deal, Nycomed has agreed to make an equity
investment of $40 million, pay NPS up to $25
million in milestones upon regulatory approvals
and achievement of certain sales targets and pay
NPS royalties.(3)NPS Pharmaceuticals and Nycomed
Announce US$90+Million PROS(R) Marketing Agreement
for Europe, Press Release, April 21, 2004.
Its experimental medicine for osteoporosis, AMG
`162, would likely enter Phase III trials. This
product would be taken only
once-every-six-months, compared to daily or
weekly pills available on the market, such as
Merck's Fosamax and
Update-Amgen unveils drug pipeline; stock drops by Jed
Seltzer and Ransdell Pierson, Reuters, March 23, 2004
An experimental pneumonia vaccine developed by
Wyeth Pharmaceuticals has been confirmed by
studies that it could save the lives of children in
Africa. The study tested the vaccine on more than
17,000 children in Gambia and found that it could
reduced the chances of getting pheumonia by
Study confirms pneumonia vaccine could save children's
lives in Africa, Emma Ross, Canadian Press, March l25,
Prostate Drug Combo
FDA has approved use of Merck's Proscar with
Pfizer's Cardura for enlarged prostates. Cardura
has first quarter sales of $148 million while
Proscar had Q4 sales of $168 million. Our View:
The sales for both are huge. It is worthwise to
develop a combo tablet containing both drugs.
Related News: Upate 1-Merck says FDA approves prostate
drug combo, Reuters, April 20, 2004
REPIRATORY TRACT INFECTIONS
Abbott Laboratories Inc. received a new patent for
Biaxin XL, the extended-release form of
clarithromycin. They think, this can block a handful
rivals from launching generic versions of the drug.
Abbott shares rise on new Biaxin patent, BusinessWeek
online, March 29, 2005.
Rituxan improved symptoms in patients with
moderate to severe rheumatoid arthritis when
taken with methrotrexate, another arthritis drug.
Genentech (majority owned by Roche Group) said
Rituxan is a therapeutic antibody that selectively
depletes B-lymphocytes which play a central role
in rheumatoid arthiritis..Extracted fromDrug Companies
Say Rituxan is Promising, Associated Press, June 16, 2004.
Another experimental medicine for rheumatoid
arthritis, AMG 714, showed an ;extremely good
safety profile&quot; and it should complete
Phase II trials this year. While, Panitumumab is in
Source: Update-Amgen unveils drug pipeline; stock drops
by Jed Seltzer and Ransdell Pierson, Reuters, March 23,
Short Bowel Syndrome
This is a pivotal Phase III study (80 patients, six
months) for this investigational drug-teduglutide.
Teduglutide is an analog of glucagon like peptide
2 (GLP-2), a naturally occurring hormone that
regulates the growth, proliferation and
maintenance of cells lining the gastrointestinal
tract. Teduglutide was able to increase the size
and number of these cells in previous animal and
human clinical trials. There are about
16,000-20,000 adult SBS patients in the US. On
the other hand, teduglutide is being tested in a
Phase II study in patients with Crohn's disease (2).
Related News:(1) NPS Begins Pivotal Study With
Teduglutide in Patients With Short Bowel Syndrome (SBS)
April 6, 2004 (2) NPS Osteoporosis Drug Proves Effective
in Trial; March 30, 2004
THROMBOCYTHEMIA Thrombocythemia is a
condition where the concentration of platelets in
the blood rises above normal levels and can result
in blood clots. Ivax Corp., Barr Pharmaceuticals,
Inc. and Mylan Laboratories Inc. received approval
from FDA to market generic versions of Shire
Pharmaceuticals Group's Agrylin. Currently, the
annual sales of Agrylin are about $106 million.
Three Drug Makers Get Generic Agrylin OK, Associated
Press, April 18, 2005.
Impax' generic verion of Ditropan XL got a tentative
approval from FDA.
The Allure of Impax, Gen G. Marcial, Businessweek
Online, March 14, 2005